ValuEngine lowered shares of Xenon Pharmaceuticals (NASDAQ:XENE) from a buy rating to a hold rating in a research note issued to investors on Tuesday morning, ValuEngine reports.

Other research analysts also recently issued research reports about the company. Guggenheim assumed coverage on Xenon Pharmaceuticals in a research note on Friday, September 20th. They issued a buy rating and a $25.00 target price for the company. Zacks Investment Research upgraded Xenon Pharmaceuticals from a hold rating to a buy rating and set a $10.00 price target on the stock in a research report on Saturday, October 26th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. Xenon Pharmaceuticals presently has an average rating of Buy and an average price target of $17.67.

Xenon Pharmaceuticals stock opened at $13.88 on Tuesday. Xenon Pharmaceuticals has a one year low of $5.41 and a one year high of $14.44. The business has a fifty day moving average price of $9.63 and a 200-day moving average price of $9.50. The company has a debt-to-equity ratio of 0.18, a current ratio of 8.25 and a quick ratio of 8.25. The firm has a market capitalization of $342.12 million, a P/E ratio of -10.44 and a beta of 1.43.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.49) by $0.16. The company had revenue of $3.50 million during the quarter. Sell-side analysts expect that Xenon Pharmaceuticals will post -1.66 earnings per share for the current fiscal year.

In related news, CEO Simon N. Pimstone sold 10,395 shares of the business’s stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $9.51, for a total transaction of $98,856.45. Following the completion of the transaction, the chief executive officer now directly owns 258,122 shares in the company, valued at $2,454,740.22. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Frank A. Holler sold 5,069 shares of the company’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $9.32, for a total value of $47,243.08. Following the completion of the transaction, the director now owns 136,129 shares in the company, valued at $1,268,722.28. The disclosure for this sale can be found here. Insiders sold a total of 23,087 shares of company stock worth $216,766 over the last quarter. Corporate insiders own 8.35% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the company. Point72 Asset Management L.P. grew its holdings in shares of Xenon Pharmaceuticals by 8.8% during the second quarter. Point72 Asset Management L.P. now owns 925,000 shares of the biopharmaceutical company’s stock worth $9,121,000 after purchasing an additional 75,000 shares in the last quarter. NEA Management Company LLC grew its stake in Xenon Pharmaceuticals by 229.8% in the 3rd quarter. NEA Management Company LLC now owns 602,663 shares of the biopharmaceutical company’s stock worth $5,430,000 after buying an additional 419,909 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Xenon Pharmaceuticals by 0.7% in the 2nd quarter. Renaissance Technologies LLC now owns 475,500 shares of the biopharmaceutical company’s stock worth $4,688,000 after buying an additional 3,200 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of Xenon Pharmaceuticals in the 2nd quarter worth $2,244,000. Finally, Altshuler Shaham Ltd raised its position in shares of Xenon Pharmaceuticals by 4.3% during the 2nd quarter. Altshuler Shaham Ltd now owns 149,758 shares of the biopharmaceutical company’s stock valued at $1,477,000 after buying an additional 6,151 shares in the last quarter. Hedge funds and other institutional investors own 62.24% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals, Inc engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P.

Read More: Trading Strategy Methods for Individual Investors

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.